Biosimilar Tipping Point: Five Questions For Henlius CEO
Now valued at close to $3bn, Henlius is one of the largest biotech unicorns in China. CEO Scott Liu sat down with Scrip in an exclusive interview to discuss biosimilar development in China, emerging market expansion plans, and its venture into immuno-oncology combo strategy.
You may also be interested in...
European regulators have accepted for review a marketing authorization application for the first ‘China-developed’ biosimilar, a version of Roche’s blockbuster breast-cancer drug Herceptin (trastuzumab) developed by Chinese biotech firm Henlius.
Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile active ingredient supply chain.